Form 4: Regeneron Director Bonnie L. Bassler Executes Stock Option and Sells Shares Under 10b5-1 Plan

Bonnie L. Bassler, a director at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on June 5, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 5, 2024, Bonnie L. Bassler, a director of Regeneron Pharmaceuticals, exercised a non-qualified stock option to acquire 827 shares of common stock at a price of $380.95 per share.
• Simultaneously, Bassler sold 827 shares of Regeneron common stock at a price of $1,011 per share.
• These transactions were executed under a pre-arranged trading plan (Rule 10b5-1(c)) adopted on February 27, 2024.
• Following these transactions, Bassler directly owns 1,382 shares of Regeneron common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the director's confidence in the company.

Industry Context

Directors often use 10b5-1 plans to diversify their holdings and avoid accusations of insider trading. This is a common practice among corporate executives.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the pharmaceutical industry like Amgen (AMGN) and Johnson & Johnson (JNJ), to manage their stock transactions.
• The reported transactions are similar to those of other directors who utilize these plans to exercise stock options and sell shares, ensuring compliance with insider trading regulations.

Key Dates